The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 20 - 65 |
| Updated: | 11/30/2013 |
| Start Date: | June 2011 |
| End Date: | September 2013 |
| Contact: | Paula Giesler, RN |
| Email: | giesler.paula@mayo.edu |
| Phone: | 507-255-8345 |
The study is being undertaken to understand how a gastric bypass can affect a subject's
diabetes even prior to their losing significant amounts of weight. The hypothesis of this
study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration
in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.
Inclusion Criteria:
- Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of >
110 mg/dL
- Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).
Exclusion Criteria:
- Subjects taking thiazolidinediones
- Subjects with active systemic illness
- Subjects with active microvascular or macrovascular complications of their diabetes
- For female subject: positive pregnancy test at the time of enrollment in study
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
